SUNNYVALE, Calif., Nov. 14 /PRNewswire-FirstCall/ --
Scios, Inc. (Nasdaq: SCIO) today announced that four abstracts related to
Natrecor(R) (nesiritide) will be presented at American Heart Association's
(AHA) Scientific Sessions 2002 conference in Chicago.
"We are pleased to participate in the AHA Scientific Sessions meeting, one
of the premier cardiology conferences in the world, and look forward to
meeting with a wide variety of physicians to discuss the use of Natrecor to
treat patients suffering from acutely decompensated congestive heart failure,"
said Richard B. Brewer, president and chief executive of Scios.
The four posters to be presented at AHA Scientific Sessions are:
-- (Abstract #109353) Nesiritide (B-Type Natriuretic Peptide) Use in
Patients with Renal Insufficiency and Acute Decompensated Heart
Failure: Efficacy and Safety Results from the VMAC Trial, by Javed
Butler, M.D. MPH, Cardiology Division Vanderbilt University Medical
Center. This poster presentation will take place on Tuesday, November
19th from 11:00 am - 1:00 pm.
-- (Abstract # 101803) The Effects of Nesiritide on Serum Levels of B-Type
Natriuretic Peptide (BNP) in Patients admitted for Decompensated
Congestive Heart Failure, by Alan S. Maisel M.D., of the San Diego VA
Healthcare Center, San Diego. This poster presentation will take place
on Tuesday, November 19th from 4:00 - 6:00 pm.
-- (Abstract #102399) Admission Endothelin-1 Levels in Patients with
Decompensated Heart Failure Predict Short-Terms Survival After
Discharge, by Doron Aronson, M.D., et al; Rambam Medical Center, Haifa,
Israel. This poster presentation will take place on Tuesday, November
19th from 4:00 - 6:00 pm.
-- (Abstract # 100856) Measures of Heart Rate Variability in Hospitalized
Patients with Decompensated Heart Failure Predict Survival After
Discharge, by Doron Aronson, M.D., et al; Rambam Medical Center, Haifa,
Israel. There will be an oral presentation of this poster from
3:45 - 4:00 pm on Tuesday, November 19th.
Scios also is supporting a dinner symposium during the meeting, entitled
"Spanning the Spectrum of Care in Acute Decompensated Heart Failure: The Role
of Natriuretic Peptides," that will take place on Monday, November 18, from
6:00 - 8:00 p.m. at The Field Museum. Moderated by Marc A. Silver, M.D.,
Clinical Professor and Chairman, Department of Medicine, Director Heart
Failure Institute, Advocate Christ Hospital and Medical Center, Oak Lawn, IL,
the session will address the role of nesiritide to treat heart failure in a
variety of clinical settings.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
Forward-Looking Safe Harbor Statement
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "estimate," "believe," "intend," "expect," "may," "should,"
"plan," "project," "contemplate," "anticipate" or similar statements.
Statements that are not historical facts are forward-looking statements based
on current assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of Natrecor and our pipeline products, including
SCIO-469 and inhibitors to TGF-beta, our ability to partner the development
and commercialization of our pipeline products and Natrecor (outside the U.S.
and Europe) with third parties on favorable terms, or at all, as well as other
risks detailed from time to time in the reports filed by Scios with the SEC,
including the Company's quarterly reports and annual report on Form 10-K.
Actual results, performance or achievements of Scios may differ significantly
from those described in these forward-looking statements. Scios disclaims any
intention or obligation to update or revise any financial projections or
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Scios, Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Media and Investors, Suzanne Beveridge of
Scios, Inc., +1-408-616-2947; or Media, Jim Weiss of WeissCom
Partners, Inc., +1-415-260-1274, for Scios, Inc.; or Investors,
Fern Lazar or Sara Moorin, both of Lazar Partners Ltd.,
+1-212-867-1762, for Scios, Inc.
|
